Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Financial Information for the Company's Reportable Segments

The following tables present financial information for the Company's reportable segments for the periods indicated (in thousands):

	Three Months Ended March 31, 2025
	Finance Receivables		Pharmaceutical Development and Other		Holding Company and Other		Consolidated
Revenue	$	10,712	$	963	$	—	$	11,675
Other revenue	110		47		—		157
Benefit from credit losses	(1,465)		—		—		(1,465)
Interest expense	232		2		896		1,130
Pharmaceutical manufacturing, research and development expense	—		758		—		758
Depreciation and amortization expense	—		—		19		19
General and administrative expense	55		704		2,518		3,277
Other expense, net	(2,214)		(82)		—		(2,296)
Income tax expense	—		—		1,278		1,278
Net income (loss)	9,786		(536)		(4,711)		4,539

	Three Months Ended March 31, 2024
	Finance Receivables		Pharmaceutical Development and Other		Holding Company and Other		Consolidated
Revenue	$	11,035	$	279	$	—	$	11,314
Other revenue	46		—		—		46
Provision for credit losses	5,297		—		—		5,297
Interest expense	1,256		—		—		1,256
Pharmaceutical manufacturing, research and development expense	—		530		—		530
Depreciation and amortization expense	—		492		22		514
General and administrative expense	78		710		1,896		2,684
Other expense, net	(382)		—		—		(382)
Income tax benefit	—		—		229		229
Net income (loss)	4,068		(1,453)		(2,147)		468

Schedule of Total Assets for the Company's Reportable Segments

The following table presents total assets for the Company's reportable segments for the periods indicated (in thousands):

	March 31, 2025		December 31, 2024
Total Assets
Finance receivables	$	297,961	$	299,248
Pharmaceutical development and other	9,013		7,786
Holdings Company and other	24,290		25,201
Total	$	331,264	$	332,235